A5049397005- Amyloidosis: Diagnosis, Treatment, Outcomes
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Drug Transport and Resistance Mechanisms
- Histone Deacetylase Inhibitors Research
- CAR-T cell therapy research
- Central Venous Catheters and Hemodialysis
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Antibiotic Use and Resistance
- Hormonal Regulation and Hypertension
- Venous Thromboembolism Diagnosis and Management
- Quinazolinone synthesis and applications
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Complement system in diseases
- Renin-Angiotensin System Studies
- Childhood Cancer Survivors' Quality of Life
- Viral-associated cancers and disorders
- Sodium Intake and Health
- Renal Transplantation Outcomes and Treatments
- Gout, Hyperuricemia, Uric Acid
Princess Alexandra Hospital
2013-2024
The University of Queensland
2017-2020
Mater Adult Hospital
2017-2019
Royal Brisbane and Women's Hospital
2013
The University of Melbourne
2001
Abstract Blockade of the PD-1 axis has modest efficacy in diffuse large B-cell lymphoma (DLBCL), but data regarding LAG3 are sparse. The impact digital gene expression was tested 309 patients with DLBCL treated standard chemoimmunotherapy. Cellular distribution protein determined by immunohistochemistry and flow cytometry. In tumor-infiltrating lymphocytes (TILs), highest on CD4+ regulatory T cells (Tregs) also highly expressed CD8+ compared non-Tregs (both P = .008). LAG3high TILs were...
PURPOSE A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. METHODS Patients either MRD (≥1 log 10 rise) relapse (blasts 5%-15%) received 600 mg once daily D1-28 plus LDAC D1-10 28-day cycles. The primary objective was response cohort complete remission (CR/CRh/CRi) cohort. RESULTS Forty-eight adults (n = 26) 22) were enrolled. Median age 67 years...
Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role patients who are treated with intensive chemotherapy. The European LeukemiaNet defined molecular persistence at low copy number (MP-LCN) as MRD transcript level <1% to 2% a <1-log change between any 2 positive samples collected after the end treatment (EOT). Because clinical impact MP-LCN is unknown, we sought characterize outcomes persistent NPM1mut EOT and identify...
Thrombotic microangiopathy (TMA) is a microvascular occlusive disorder characterised by platelet aggregation, thrombocytopenia and end-organ damage. It commonly idiopathic, although several drug classes, including cytotoxic chemotherapy, have been implicated. Several of cases gemcitabine-induced TMA documented with incidence likely to increase the escalating use gemcitabine. We report two patients who developed while on gemcitabine chemotherapy.
Management practices in early-stage (I/II) follicular lymphoma (FL) are variable and include radiation (RT), systemic therapy, or combined modality therapy (CMT). There is a paucity of data regarding maintenance rituximab this cohort. We conducted an international retrospective study patients with newly diagnosed FL staged positron emission tomography (PET)-computed bone marrow biopsy. Three hundred sixty-five (stage I, n = 221), median age 63 years, treated from 2005-2017 were included,...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Light-chain (AL) amyloidosis arises from a plasma cell clone that overproduces immunoglobulin light chains. These chains deposit within tissues organs interfere with normal function. Frequently, cardiac, hepatic, renal involvement contribute to the major morbidities observed in this rare disease. Current treatment of AL targets rapidly reduce level circulating Recently, addition subcutaneous daratumumab standard...
Altered operation of the renin-angiotensin-aldosterone system (RAAS) and dietary sodium intake have been identified as independent risk factors for cardiac hypertrophy. The way in which interact pathogenesis hypertrophy is poorly understood. aims this study were to investigate effects renin-angiotensin (RAS) blockade spontaneously hypertensive rat (SHR), using co-treatment with an angiotensin II receptor blocker (ARB) angiotensin-converting enzyme (ACE) inhibitor different intakes. Our...
<h3>Objectives</h3> Hereditary Transthyretin amyloidosis (ATTRv) is characterised by progressive sensorimotor and autonomic neuropathy, cardiac failure. We aim to describe the spectrum of ATTRv neuropathy in Australia. <h3>Methods</h3> A retrospective analysis patients attending Australian Amyloidosis Network clinics between 2007–2022 was performed. TTR variants, clinical features treatments were evaluated. <h3>Results</h3> 161 individuals identified (62% NSW/ACT, 20% QLD, 12% VIC/TAS, 4%...